Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-09-12
1999-03-02
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514414, 514419, 548113, 5483124, 5483647, 548492, 548493, A61K 31405, C07D20914, C07D23102, C07F 928
Patent
active
058771972
ABSTRACT:
This invention is directed to novel (N-substituted)indole ICE/ced-3-inhibitor compounds. The invention is also directed to pharmaceutical compositions of such indole compounds, plus the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, and for the treatment of ischemic injury.
REFERENCES:
patent: 5486623 (1996-01-01), Zimmerman et al.
patent: 5498616 (1996-03-01), Mallamo et al.
patent: 5514694 (1996-05-01), Powers et al.
Bodanzky, M., "Peptide Chemistry, A Practical Textbook," 2nd rev. ed., Springer-Verlag, Berlin Heidelberg, 55-73 and 129-180 (1993).
Bodanzky, M., "Principles of Peptide Synthesis," Hafner et al., Eds., Springer-Verlag, Berlin Heidelberg, pp. 9-52 and pp. 202-251 (1984).
Gagliardini et al., "Prevention of Vertebrate Neuronal Death by the crmA Gene", Science, 263:826-828 (1994).
Howard et al., "IL-1-Converting Enzyme Requires Aspartic Acid Residues for Processing of the Il-1.beta. Precursor at two Distinct Site and Does Not Cleave 31-kDa Il-1.alpha.", J. Immunol., 147:2964-2969 (1991).
Jones, "Amino Acid and Peptide Synthesis," Steven G. Davis ed., Oxford University Press, Oxford, pp. 25-41 (1992).
Lonnemann, et al., "Differences in the Synthesis and Kinetics of Release of Interleukin 1.alpha., interleukin 1.beta. and tumor necrosis factor from human mononuclear cells", Eur. J. Immunol., 19:1531-1536 (1989).
Marx, J., "Cell Death Studies Yield Cancer Clues", Science, 259:760-762 (1993).
Miura, M. et al., "Induction of Apoptosis in Fibroblasts by IL-1.beta.-Converting Enzyme, a Mammalian Homolog for the C. elegans Cell Death Gene ced-3", Cell, 75:653-660 (1993).
Mosely, et al., "Determination of the minimum polypeptide lengths of the functionally active sites of human interleukins 1.alpha. and 1.beta.", Proc. Nat. Acad. Sci., 84:4572-4576 (1987).
Nett-Fiordalisi, et al., "Macrophage Apoptosis in the Absence of Active Interleukin-1.beta.-Converting Enzyme", Journal of Leukocyte Biology, 58:717-724 (1995).
Nicholson et al., "Identification and Inhibition of the ICE/CED-3 Protease necessary for Mammalian Apoptosis", Nature, 376:37-43 (1995).
Oppenheim, et al., "There is more than one Interleukin 1", Immunology Today, 7:45-56 (1986).
Plattner, J.J. and D.W. Norbeck, in Drug Discovery Technologies, C.R. Clark and W.H. Moos, Eds. (Ellis Horwood, Chichester, England, 1990), pp. 92-126.
Sleath et al., "Substrate Specificity of the Protease That Processes Human Interleukin-1.beta.", J. Biol. Chem., 265:14526-14528 (1992).
Thornberry et al., "A Novel Heterodimeric Cysteine Protease is Required for Interleukin-1.beta. Processing in Monocytes", Nature, 356:768:774 (1992).
Yuan et al., "The C. elegans Cell Death Gene ced-3 Encodes a Protein Similar to Mammalian Interleukin-1.beta.-Converting Enzyme", Cell, 75:641-652 (1993).
Bai Xu
Karanewsky Donald S.
Oswecki Jane C.
Richter Johann
LandOfFree
C-terminal modified (N-substituted)-2-indolyl dipeptides as inhi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C-terminal modified (N-substituted)-2-indolyl dipeptides as inhi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-terminal modified (N-substituted)-2-indolyl dipeptides as inhi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-423259